Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900522 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT01900522 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 76 participants.
The verdict
NCT01900522, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
Interventions
- DRUG Placebo
- DRUG ITI-214 Dose A
- DRUG ITI-214 Dose B
- DRUG ITI-214 Dose C
- DRUG ITI-214 Dose D (Elderly)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900522
The ClinicalTrials.gov registry entry for NCT01900522 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01900522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900522 about?
NCT01900522 is a clinical study titled "Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia". The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
What is the current status of trial NCT01900522?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2013-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01900522?
The interventions under investigation include: Placebo (DRUG), ITI-214 Dose A (DRUG), ITI-214 Dose B (DRUG), ITI-214 Dose C (DRUG), ITI-214 Dose D (Elderly) (DRUG).
Who is sponsoring clinical trial NCT01900522?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.